Delving into the Latest Updates on Cellemedy Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Digestive System Disorders

Protein drugs

Protein drug conjugate

Fusion protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	8

Top 5 Drug Type	Count

Protein drugs	5
Protein drug conjugate	2
Fusion protein	1

Top 5 Target	Count

HER2(Receptor tyrosine-protein kinase erbB-2)	2
EGFR x HER2 x MSLN	1
PDL1(Programmed death-ligand 1)	1
LAG3 x PDL1	1
PD-1(Programmed cell death protein 1)	1

AbstractImmune checkpoint inhibitors play a crucial role in current cancer treatments, serving as promising therapeutic options across various cancer types. In particular, PD-L1/PD-1 immune checkpoint inhibitors have been at the forefront of this field. However, recent concerns have been raised regarding the risk-benefit ratio of treatment based on PD-L1 expression levels, prompting the need for the development of immune checkpoint therapies that demonstrate high efficacy regardless of whether PD-L1 expression is high or low. Cellemedy’s T-sphaera platform based multi-target immune checkpoint inhibitors that simultaneously act on multiple immune targets, regardless of target expression levels. This platform offers several advantages: 1) it introduces biologically active domains that exhibit therapeutic effects, 2) it demonstrates high avidity based on protein structural characteristics, 3) it inherently possesses a cancer-T cell engaging effect when introducing multi-targets, and 4) being human protein-based results in reduced immune-related side effects, contributing to a favorable safety profile and therapeutic index. Cellemedy’s multi-target immune checkpoint inhibitors exhibit target-specific cytotoxicity against melanoma cancer cell line. In a non-human toxicity study, those compounds were well tolerated during repeated dosing, providing evidence of a superior safety profile without noticeable side effects. Furthermore, we verified strong efficacy in in vivo studies through T/NK cell engagement and high target avidity following a single-dose administration. Rapid and durable anti-tumor responses have been observed in vivo models. In summary, Cellemedy’s T-sphaera is promising multi-target immune checkpoint inhibitor platform that can be designed for various target, not only immune checkpoint blockade but also other tumor receptors, aiming at multiple cancers.Citation Format:Bo-Ram Lee, Seon-Boon Lee, Chul Joo Yoon, Hyunju Hwang, Sunho Jung, Joon Heo, Kyung-Mi Lee, H. Chris Kim. A Novel Therapeutic Approach : New Drug Candidate with are potent and safe next-generation multi-target immune checkpoint inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7302.

100 Deals associated with Cellemedy Co., Ltd.

Login to view more data

100 Translational Medicine associated with Cellemedy Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

5

3

Preclinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TSIT-01 ( PDL1 x TIGIT )	Solid tumor More	Preclinical
TSDC-02 ( HER2 )	Solid tumor More	Preclinical
TSDC-01 ( EGFR x HER2 x MSLN )	Solid tumor More	Preclinical
TSIT-05 ( HER2 )	Solid tumor More	Discovery
TSIT-04 ( PD-1 )	Solid tumor More	Discovery